Mesa Laboratories, Inc. (MLAB): Initiation Report (Coverage: FY2024-Q1 FY2027)
Key Points
- Portfolio and Market Position: Mesa Laboratories is a global provider of quality control instruments and consumables for regulated pharmaceutical, healthcare, and life sciences markets. The company operates four main segments: Sterilization & Disinfection Control (SDC), Biopharmaceutical Development (BPD), Calibration Solutions, and Clinical Genomics.
- Growth and Profitability: Revenue grew from $216.2M in FY2024 to $249.1M in FY2026 (+3.4% YoY in FY2026). Gross margins improved steadily, reaching 63.5% in FY2026. Q1 FY2027 revenue was $60.1M (+1% YoY), with gross margin expanding to 64.9%.
- Segment Dynamics: SDC is the largest and most profitable segment but faced delivery reliability issues in Q1 FY2027. BPD rebounded after a prior sharp decline. Calibration Solutions showed consistent growth. Clinical Genomics remains challenged, especially in China.
- Profit Recovery and Balance Sheet: Net income rebounded to $6.7M in FY2026 from a loss of -$2.0M in FY2025 (which had been impacted by impairment charges). Net leverage reduced to 1.85x in Q1 FY2027, with a focus on deleveraging and internal investment.
- Strategic Shift: New CEO (appointed ~100 days before Q1 FY2027 call) is shifting focus from M&A to operational execution and organic growth, emphasizing customer loyalty and margin expansion.
- Risks: Key risks include SDC delivery reliability, Clinical Genomics exposure to China, FX/tariff headwinds, customer concentration, and litigation.
Business Overview
Mesa Laboratories provides critical quality control solutions across four segments:
| Segment | FY2026 Revenue ($M) | % of Total |
|---|---|---|
| Sterilization & Disinfection | 101.6 | 40.8% |
| Biopharmaceutical Development | 48.6 | 19.5% |
| Calibration Solutions | 53.6 | 21.5% |
| Clinical Genomics | 45.4 | 18.2% |
| Total | 249.1 | 100.0% |
- 53% of FY2026 revenue was generated outside the U.S.
Financial Snapshot: Fiscal Years Ended March 31
| Fiscal Year Ended | Revenue ($M) | YoY Growth | Gross Profit ($M) | Gross Margin (%) | Operating Income ($M) | Net Income ($M) | Diluted EPS ($) | Cash ($M) | Working Capital ($M) |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 249.1 | +3.4% | 158.3 | 63.5 | 18.5 | 6.7 | 1.21 | 26.9 | 44.4 |
| 2025-03-31 | 241.0 | +11.5% | 150.9 | 62.6 | 16.3 | -2.0 | -0.36 | 27.3 | -61.3 |
| 2024-03-31 | 216.2 | - | 133.3 | 61.7* | -272.1 | -254.2 | -47.20 | 28.2 | - |
*Gross margin for FY2024 calculated from disclosed revenue and gross profit.
Financial Snapshot: Q1 FY2027 vs. Q1 FY2026
| Metric | Q1 FY2027 | Q1 FY2026 | YoY Change | Notes |
|---|---|---|---|---|
| Revenue ($M) | 60.1 | - | +1% | |
| Core Organic Revenue Growth (%) | 0.4 | - | - | Excludes FX tailwind |
| Gross Profit ($M) | 39.0 | - | - | 64.9% margin (+290 bps YoY) |
| GAAP Operating Income ($M) | 7.0 | - | +129% | |
| Adjusted Operating Income ($M) | 15.0 | - | +16.5% | $2.61/diluted share |
| AOI excl. unusual items (TTM, $M) | 66.0 | 63.5 | +2.5 | Trailing 12 months |
| Net Income ($M) | 2.8 | - | -40.3% | Driven by non-operating FX swing |
| Diluted EPS ($) | 0.49 | - | - | |
| Operating Cash Flow ($M) | 14.7 | 1.9 | +12.8 | Stronger collections, improved ops |
| Cash & Equivalents ($M) | 30.7 | 26.9 | +3.8 | QoQ |
| Net Leverage Ratio (x) | 1.85 | - | - | Targeting 1.5-1.75x by FY27 end |
| Debt Repaid ($M) | 8.7 | - | - | Q1 2027 |
Segment Performance: FY2026
| Segment | Revenue ($M) | YoY Growth | Gross Margin (%) | Notes |
|---|---|---|---|---|
| Sterilization & Disinfection | 101.6 | +8.7% | 70.6 | Price increases, FX tailwinds, GKE integration |
| Biopharmaceutical Development | 48.6 | -0.2% | 58.7 | Immunoassay declines offset by peptide growth |
| Calibration Solutions | 53.6 | +3.5% | 59.7 | Price increases, service contract renewals |
| Clinical Genomics | 45.4 | -3.6% | 57.3 | China macro/trade headwinds; ex-China +9.2% |
Segment Performance: Q1 FY2027
| Segment | Revenue ($M) | YoY Growth (%) | Gross Profit % | Notes |
|---|---|---|---|---|
| SDC | 24.5 | -3.6 | -150 bps YoY | Delivery reliability issue, not demand |
| BPD | 12.1 | +5.0 | +800 bps YoY | Recovery after prior -30% decline; new GM, Gyrolab focus |
| Calibration Solutions | 13.3 | +7.6 | +350 bps YoY | Recurring, steady performer |
| Clinical Genomics | 10.3 | -0.1 | +790 bps YoY | China down -7%, ex-China up +0.6%; managed for cost/returns |
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Durable, regulation-embedded franchises with recurring revenue | SDC delivery reliability issues causing revenue volatility |
| Strong gross margin expansion (FY2026: 63.5%; Q1 FY2027: 64.9%) | Clinical Genomics segment remains flat, with China still declining |
| Balance sheet strengthening (net leverage down to 1.85x, strong cash flow in Q1 FY2027) | Non-operating FX swings impacting net income |
| Focus on operational execution and self-help over risky M&A | SDC backlog not yet durably fixed; episodic improvements |
| BPD segment returned to growth after steep prior decline | No full-year guidance provided until November 2026 |
| Next-gen Gyrolab platform in development, launch expected FY2028 | Potential customer frustration and risk of lost loyalty due to late deliveries in SDC |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Durable fix to SDC delivery reliability, unlocking high-margin revenue | Continued or worsening SDC fulfillment delays |
| Launch of next-gen Gyrolab platform (expected FY2028) | Loss of customer loyalty in SDC due to repeated late shipments |
| Further deleveraging and improved capital allocation | Prolonged weakness in Clinical Genomics, especially China |
| Sustained margin expansion and cost discipline | Adverse FX movements impacting non-operating results |
